P
hysical therapists strive to create interventions that focus on improving a patient's functional ability. Function gained during or after therapy often is measured by change in scores on a functional assessment instrument over time. 1 When results improve from one assessment to another, therapists often assume that the patient has progressed. Unfortunately, there is a chance the difference between assessments is a result of measurement error. 2 A common problem involves deciding whether the results are clinically significant or an error in measurement. To determine whether an improvement is significant, researchers need to provide minimal detectable change (MDC) scores, by patient population, for tests. Minimal detectable change is defined as the minimal amount of change that is not due to variation in measurement. 3 Clinicians can interpret MDC scores as the minimal change that is not due to error. Scores at or above the MDC level are due to patient improvement on the test rather than measurement error. Measurement error includes expected or typical variability in patient performance. In the literature, various methods are utilized to calculate change scores, including the standard error of measurement (SEM), minimal clinically important difference (MCID), and smallest detectable difference (SDD). The SEM is calculated by multiplying the standard deviation by ͌1 minus the reliability coefficient, which is the stability or variability of response and indicates the range of the scores that can be expected upon retesting. 4 The MCID is the smallest meaningful change, as judged by the patient or experts in the field, 3 and is determined by questioning or observing the patient. Some researchers refer to the MDC utilizing a 95% confidence interval (MDC 95 ) as the SDD. 5 Once the MDC is determined on a particular test for a given population, therapists can interpret whether the change score for their patient is at or above the minimal level of detectable change reported in the literature. If the patient's score is less than the MDC value, it is considered to be indistinguishable from measurement error. Accordingly, a patient who demonstrates less than the MDC value is viewed as not benefiting from the intervention. For example, following hip fracture, the MDC is 0.08 m/s for comfortable gait speed. 6 If a patient's comfortable gait speed increases less than 0.08 m/s, the change is within measurement error, leading to the conclusion that a clinically significant change did not occur as a result of the therapeutic intervention.
To evaluate MDC, researchers first must measure test-retest reliability. On functional tests, a 7-day separation period typically is used. Sources of error may include inconsistencies caused by the participant's physical or mental condition, variations in the testing procedure, or tester error. Maintaining consistency and using standardized protocols for testing, such as using the same tester, setup, testing order, and time of day, can improve test-retest reliability.
The MDC is based on the SEM and is calculated using the following formula 3 : MDC ϭ z-score level of confidence ϫ SD baseline ϫ ͌(2[1Ϫr test-retest ]).
The z-score represents the confidence interval from a normal distribution, SD is the standard deviation at baseline, and r is the test-retest reliability coefficient. The multiplier of ͌2 is used to account for the additional uncertainty introduced by using difference scores from measurements at 2 points in time. Some researchers 1,3 suggest using a confidence interval of 90% due to its use being more common in the literature; however, a confidence interval of 95% increases the precision of score estimation and is the SDD. 3 Internal consistency, determined by the Cronbach alpha, of a multipleitem test such as the Berg Balance Scale (BBS), the Activities-specific Balance Confidence (ABC) Scale 27 In 2 studies, MDC 95 scores for the SRT with eyes open ranged from 9 to 10 seconds, 25 and MDC 95 scores for the SRT with eyes closed ranged from 3 to 9 seconds. 25, 26 Test-retest studies are needed on the RT and SRT for populations with neurological disorders, including people with PD.
ABC Scale
The ABC Scale is a 16-item questionnaire used to measure balance confidence in specific situations, with scores ranging from 0% to 100%. 39 50 m for subjects with peripheral arterial occlusive disease, 41 51 m for subjects with cardiac rehabilitation, 38 and 74, 86, and 90 m for subjects with heart failure. 40 One study 42 44 and 18 m for subjects with lung disease. 39 One study 46 reported an MCID of 54 m for subjects with COPD. Standard deviations were variable, sample sizes ranged from 15 to 470 subjects, and days between tests ranged from 1 to 10.
Two studies 47, 48 assessed test-retest reliability in older adults, with ICCs of .87 and .93. The MDC values were 77 m for community-dwelling elderly subjects, 48 89 m for those living in retirement homes, 47 and 94 m for those living in community centers. 47 Sample sizes ranged from 5 to 22 subjects, and days between tests ranged from 7 to 14. Overall, the 6MWT is a reliable test, with different MDC 95 values by client population. Minimal detectable change studies with larger samples are needed on the 6MWT for people with neurological diseases, including those with PD.
TUG
The TUG is a mobility test for the geriatric population. It includes a sit- 57 In one study, 58 MDC 95 values of 0.06 to 0.14 m/s for comfortable gait speed and 0.08 to 0.15 m/s for fast gait speed were calculated for four 10-year cohort groups over the age of 60 years.
Three studies assessed test-retest reliability in patients with musculoskeletal problems, including osteoporosis, 60 knee osteoarthritis, 61 and hip fracture. 21 Intraclass correlation coefficients ranged from .88 to .97 for comfortable gait speed 60 -62 and from .91 to .94 for fast gait speed. 21, 60 The MDC 95 values for comfortable and fast gait speeds were 0.25 and 0.30 m/s, respectively, for people with osteoporosis 60 and 0.49 and 0.51 m/s for people with hip fracture. 21 Overall, the MDC 95 values for both comfortable and fast gait speeds appeared to be about 0.25 m/s or less for populations tested to date, except for patients with hip fracture, with an MDC 95 value of approximately 0.50 m/s.
SF-36
The SF-36 is a quality-of-life questionnaire developed as a part of the Medical Outcomes Study to assess 8 physical and mental health concepts as seen from the respondent's point of view. These concepts are: (1) limitations in physical activities because of health problems (Physical Functioning), (2) limitations in social activities because of physical or emotional problems (Social Functioning), (3) limitations in usual role activities because of physical health problems (Role-Physical), (4) bodily pain (Bodily Pain), (5) psychological distress and well-being (Mental Health), (6) limitations in usual role activities because of emotional problems (Role-Emotional), (7) energy and fatigue (Vitality), and (8) general health perceptions (General Health). These 8 domains are relevant to general functional status and well-being. The survey was designed for selfadministration by people 14 years of age and older or for administration by a trained interviewer in person or by telephone. For each scale, item scores are coded, summed, and transformed, with final values (expressed as a percentage) ranging from 0 (worst health) to 100 (best health).
No articles were found on the testretest reliability of SF-36 scores in patients with PD; however, 17 articles were found for other populations. These articles studied patients with vestibular dysfunction 63 ; veterans 64, 65 ; adults with an intensive care unit stay of greater than 24 to 48 hours 66 ; patients with spinal cord injury 67 ; patients with confirmed or suspected ischemic stroke 68 ; patients with rheumatoid arthritis 69 ; patients with systemic lupus erythematosus 70 ; patients with knee disorders 71 ; elderly patients 72 ; patients with ulcerative colitis 73 ; patients with low back pain, menorrhagia, suspected peptic ulcer, or varicose veins 73 ; a nonclinical normative sample 74 ; and general populations in China, 75 the Basque region of Spain, 76 the Hunter region of New South Wales, Australia, 77 Japan, 78 and Sheffield, United Kingdom. 79 The time interval between tests in these studies often was 2 weeks. 64, 65, 67, 69, 71, 73, 75, 76, 78, 79 Other time intervals used were 4 weeks, 72 3 weeks, 68 1 week, 66, 70, 73, 74, 77 and 2 days. 63, 71 Fourteen studies 63-65,68 -76,78,79 were selfadministered with either paper or a computer, 2 studies 66, 67 were administered via telephone or personal interview, and 1 study 77 
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The UPDRS is the gold standard instrument used to measure disease severity in PD. It has 3 subscales: I-Mentation, Behavior, and Mood (rangeϭ0 -16), II-Activities of Daily Living (ADL) (rangeϭ0 -52), and III-Motor Examination (rangeϭ0 -108). A total score (rangeϭ0 -176) can be derived by summating the 3 subscales. Lower scores indicate a less involved disease process. The UPDRS has moderate internal consistency values across multiple studies in the 3 subscales and total score. A Cronbach alpha value of .79 has been reported for the Mentation, Behavior, and Mood subscale, 80 Cronbach alpha values of .85 to .92 have been reported for the ADL subscale, 80 -83 Cronbach alpha values of .88 to .95 have been reported for the Motor Examination subscale, 80, 81, [83] [84] [85] and a Cronbach alpha value of .96 has been reported for the total UPDRS score. 86 One study 87 examined the test-retest reliability of UPDRS scores in 400 patients with early stage, mild PD who were not taking medications. The subjects were examined on 2 occasions, separated by an average of 15 days (SDϭ8). The ICC (1,1) values were .74 for the Mentation, Behavior, and Mood subscale, .85 for the ADL subscale, .90 for the Motor Examination subscale, and .92 for the total score. The calculated MDC 95 values were 2, 4, 7, and 9, respectively. 87 In 26 ambulatory subjects with idiopathic PD and no comorbidities, test-retest reliability with a 7-day interval between tests was .84 for the Motor Examination subscale and .74 for the total score. 15 The MDCs were 13 and 15, respectively. 15 Test-retest reliability of Motor Examination subscale scores was evaluated in 34 patients with advanced PD on 2 separate occasions, 1 to 3 weeks apart, with an ICC (3,1) of . 90. 88 Minimal detectable changes of 1 to 2 points for the Mentation, Behavior, and Mood subscale, 2 to 4 for the ADL subscale, 7 to 8 for the Motor Examination subscale, and 9 for the total UPDRS encompass the existing studies. Different versions of the UPDRS are being used in studies, and a shorter version is being developed. The lower reliability of the Mentation, Behavior, and Mood subscale scores suggests the need for caution when using reliability values to calculate an MDC value. Physical therapists are most interested in the Motor Examination subscale of the UPDRS to measure responsiveness to change.
The purpose of this study was to determine the MDC 95 for people with parkinsonism on the following tests and measures: BBS, forward and backward functional reach, RT and SRT, ABC Scale, 6MWT, comfortable and fast gait speeds, TUG, the 8 subscales of the SF-36, and UPDRS (Mentation, Behavior, and Mood subscale, ADL subscale, Motor Examination subscale, and total score).
Method Subjects
Participants were recruited via bulletin advertisements and flyer distribution at local fitness centers, physical therapy sites, meal sites throughout southeast Wisconsin, Wisconsin PD organizations, church bulletins, newspapers, and other local news media. Previous research study and pro bono clinic participants also were contacted, and advertisements were placed on the Concordia University Wisconsin Web site and in faculty bulletins.
Eligibility for the study was determined by the presence of a clinical diagnosis of PD or Parkinson-plus syndrome. All potential volunteers were contacted by telephone and given an oral questionnaire. Participants were included if they were able to stand independently for 1 minute and could walk independently with or without the use of an assistive device. Participants were excluded if they reported a history of a heart condition limiting their activity level, experienced a fall as a result of dizziness or fainting within the previous 2 months, or required help with following directions.
A demographic questionnaire (sex, date of birth, date of diagnosis with PD or Parkinson-plus syndrome, ethnicity, living situation, history of falling, other medical conditions, and current medications) was completed on the first day of testing and reviewed in the participant's presence with a researcher to ensure accuracy. Participants were reminded not to change medications during their scheduled test week and to take medications at the same time on both testing days.
During the spring of 2007, 37 participants with PD (nϭ35) or Parkinsonplus syndromes (nϭ2) met all inclusion criteria and consented to participate in this study. This sample reflected the general demographics of the PD population, with more men (nϭ26) than women (nϭ11) and an elderly age distribution (mean ageϭ71 years, SDϭ12). There was a wide range of UPDRS total scores (meanϭ33/176, rangeϭ7-70), demonstrating a sample that captured a wide spectrum of disease severity. The average H&Y score was 2 (rangeϭ1-4). Distribution of H&Y stages were: 13 subjects in stage 1, 7 subjects in stage 2, 9 subjects in stage 3, 8 subjects in stage 4, and no subjects in stage 5.
The average disease duration was 14 years (SDϭ6), and participants were primarily of white/non-Hispanic descent (nϭ36), with 1 participant of Asian/Pacific descent. Of the 37 participants, 32 were living at home with another person, 3 were living at Functional Assessment in Parkinsonism home alone, and 2 were in assisted living facilities. The mean number of falls in the previous 6 months was 7 (rangeϭ0 -182); 21 participants had experienced more than one fall. None of the participants changed medications during their testing week, and all participants reported taking medications at the same time on both testing days. Thirty-one participants were using levodopa, with an average of 412 mg/d (SDϭ310, rangeϭ125-1,150). Participants, on average, had 3 comorbidities (SDϭ2, rangeϭ0 -6), including 17 with arthritis, 3 with asthma, 7 with a history of cancer, 11 with high blood pressure, 5 with low blood pressure, 1 with diabetes, 8 with a previous fracture, 9 with depression or other mental health condition, 6 with a history of heart disease, 7 with osteoporosis, 1 with stroke, and 14 with other, unspecified comorbidities.
Procedure
Testing was administered at Concordia University Wisconsin. Any classes scheduled to occur in the vicinity of the testing area were relocated to limit interruptions, and barriers were placed to ensure participant privacy. After signing consent forms, testing began with the SF-36 questionnaire and completion of the demographic information. Balance testing followed and consisted of 4 tests administered to each participant in the following order: BBS, forward and backward functional reach, RT and SRT (eyes open and eyes closed), and ABC Scale. The ambulation tests and the UPDRS were administered last and done in the following order: 6MWT, UPDRS, TUG, and comfortable and fast gait speeds. Each day total testing time per participant was approximately 1 hour. Prior to testing, all researchers were trained in their assigned test, and they performed the same duties on each testing day. Researchers who collected the reliability data were monitored by the coinvestigators before and during the testing procedures to maintain accuracy. All researchers had previous patient experience using the functional tests. If an assistive device was used, the type was documented and the participant was required to use it on the subsequent testing day. Thirty-nine participants were scheduled for the study; 2 participants cancelled due to weather or transportation issues. Researchers did not have access to the previous test results on the second day of testing.
Test-retest reliability was established over a period of 7 days in all participants, with the exception of 1 participant, who was tested 10 days apart. Although a 14-day separation may be preferred for the SF-36 questionnaire, a 7-day interval was used based on previous test-retest studies of the other functional assessments.
Balance testing. The method for the BBS test followed the original design, 7 which consists of 14 items scored on a scale of 0 to 4. A score of 0 indicates the participant was unable to complete the task, and a score of 4 indicates the participant was able to complete the task based on the assigned criteria. The floor-toseat height of the chair used on items 1, 3, 4, and 5 was 47 cm. The height of the chair without armrests used on item 5 was 44.5 cm, and the height of the step stool used on item 12 was 23 cm. A 1.27-cm (0.5-in) slipper was used on item 9. The participants were asked to perform each of the items on the original BBS, with rests as needed. The 14 items were scored by a total of 3 researchers. One researcher scored item 8 while the participants performed the FRT, another researcher scored items 7 and 13 while the participants performed the RT and SRT, and 1 researcher scored the remaining 11 items.
Equipment used for forward and backward functional reach included a level with attached wooden sliders fixed to an adjustable tripod with C rings. Participants were asked to make a fist, raise their dominant arm parallel to the floor with the elbow fully extended, and reach as far forward or backward as possible without losing their balance, lifting their feet off the ground, or touching the equipment. The foot placement and method of reach were not controlled, except to keep the arm at the height of the level. Participants who inquired about foot placement were instructed to stand in a comfortable position. Participants were allowed multiple practice trials until they performed the test correctly. Once a participant was able to perform the test correctly, 2 graded trials were completed. The dominant arm was recorded on the first testing day and used on the second testing day to maintain consistency. The averages of the 2 trials for each direction were used for data analysis, due to the high intratrial reliability reported in previous studies. 10, 89 Measurements were recorded (in centimeters) using the third metacarpal as the reference point. Two researchers participated in the data collection. One researcher gave instructions and maintained participant safety. The other researcher adjusted the equipment to match the participant's acromion height, adjusted the wooden slider during reach, and recorded initial and final measurements. The ABC Scale was administered as an interview consisting of 16 items describing various activities for which participants are asked to rate their confidence in maintaining balance on a scale of 0% (not confident) to 100% (completely confident). Final scores were determined by calculating the average score on the 16 items. To assist participants, an enlarged version of a 0 -100 scale was provided.
Ambulation. All ambulation tests were performed on a level tile floor under quiet conditions. The 6MWT was conducted in a 3-m-wide hallway with a 15-m area marked off at 1-m intervals and large cones placed at each end. Participants were read the following instructions: "When I say 'go,' I want you to walk around this track. Keep walking until I say 'stop' or until you are too tired to go any further. If you need to rest, you can stop until you're ready to go again. I am interested in measuring how far you can walk. You can begin when I say 'go.'" The following encouragements were provided: (1) after 1 minute, "You are doing well. You have 5 minutes to go."; (2) at 2 minutes, "Keep up the good work. You have 4 minutes to go."; (3) at 4 minutes, "Keep up the good work.
You have 2 minutes left."; and (4) at 5 minutes, "You are doing well. You have only 1 minute to go." Fifteen seconds prior to completion, participants were informed that time would stop shortly, and the test was stopped at 6 minutes. 90 Total distance walked was measured to the nearest meter.
For the TUG, participants were instructed to sit with their back against a chair (47 cm from floor to seat with armrests), feet behind the tape marker, and arms resting in their lap. Participants were instructed to independently rise on the word "go," comfortably walk a clearly marked distance of 3 m, turn around a cone, walk back to the chair, and sit down with their back against the chair. Time started once the participant's back left the chair and ended when the participant's back returned to the chair. Time to complete the course was measured to the nearest 100th of a second. One practice trial and 2 timed trials were performed; the 2 timed trials were averaged for data analysis.
For the test of comfortable gait speed, participants were asked to walk 10 m and were instructed to "walk at your own comfortable walking speed and stop when you reach the far line." For the test of fast gait speed, participants walked the 10 m with the instructions to "walk as fast as you can safely walk" and to stop at the far line. Time to complete the central 6 m was measured to the nearest 100th of a second using a stopwatch. Time started when any part of the foot crossed the plane of the first tapeline and ended when any part of the foot crossed the plane of the 6-m mark. Rest breaks were allowed between tests or trials, if needed. Participants completed 2 comfortable gait speed trials, followed by 2 fast gait speed trials. The 2 trials were averaged for data analysis, and gait speeds were calculated (in meters per second).
SF-36.
The SF-36 was administered via personal interview by 2 researchers using the interview script provided in the SF-36 Health Survey: Manual and Interpretation Guide. 91 Standard procedures for repeating questions and response choices were followed, as outlined in the SF-36 Health Survey: Manual and Interpretation Guide. 91 The participants were able to choose from a typed list of response choices that was enlarged and placed on a table in front of them for each question. To avoid influencing the participants' answers on the SF-36, it was the first test given to each participant on both testing days, before they were asked any other healthrelated questions.
UPDRS.
The UPDRS subscales were administered as described by Goetz and colleagues, 92 and a UPDRS total score was calculated based on the sum of the scores of the 3 subscales. The test was administered by 1 of 2 researchers, both of whom reviewed the UPDRS teaching videotape. The original 5-point (1-5) H&Y Scale staging of PD was used in the study. 93 Higher scores on the H&Y Scale indicate greater impairment of PD.
Data Analysis
Internal consistency and test-retest reliability were calculated using SPSS (version 15.0) software.* Internal consistency, assessed using the Cronbach alpha, was calculated for multiple-item tests, such as the BBS, ABC Scale, SF-36, and UPDRS. Internal consistency of .70 or greater was required on the multiple-item test before other forms of reliability were considered trustworthy. The ICC (3,k) was used instead of the Pearson * SPSS Inc, 233 S Wacker Dr, Chicago, IL 60606.
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correlation coefficient (r) for testretest reliability because it assesses rating reliability by comparing the variability of different ratings of the same subject with the total variation across all ratings and all subjects. For test-retest reliability, either a type 3,1 or type 3,2 ICC was used. The ICC (3,1) was used for the BBS, RT, SRT, ABC Scale, 6MWT, SF-36, and UPDRS because final scores on these tests were based on a single measure from one rater. The ICC (3,2) was used for the TUG, forward and backward functional reach, and comfortable and fast gait speeds because final scores for these tests were based on an average of 2 trials. Normal distribution was assessed for each outcome variable at test day 1 using a histogram plot. Data from 2 participants on the SF-36 and 1 participant on the ABC Scale were excluded from the data analysis due to the presence of cognitive deficits, as judged by the researchers administering the tests. Due to fatigue, the gait speed tests were not administered to one participant. Table 1 reports internal consistency for all multiple-item tests used in this study. All tests met the criterion of Cronbach alpha being .70 or greater, with the exception of day 1 for the Social Functioning subscale of the SF-36 and both days for the Mentation, Behavior, and Mood subscale of the UPDRS. Internal consistency from previous studies also is reported in Table 1 . In previous studies, both the SF-36 Vitality and Social Functioning subscales have had internal consistency values less than .70. The BBS and ABC Scale were the most reliable of the balance measures, with MDC 95 values of 5 and 13, respectively. The BBS and ABC Scale both demonstrated a rightskewed distribution due to a ceiling effect on these scales.
Results
Comfortable and fast gait speeds had the highest test-retest reliability, normal distributions, and MDC 95 values of 0.18 and 0.25 m/s. The 6MWT had excellent test-retest reliability and a normal distribution, but a large standard deviation that created a high MDC 95 value of 82 m. The TUG displayed a right-skewed distribution, but its test-retest reliability was low compared with the 6MWT and gait speeds.
All 8 subscales of the SF-36 had a test-retest reliability of .80 or above, except for the Social Functioning subscale. The Physical Functioning subscale, the scale most often used by physical therapists, had an MDC 95 value of 28% in our sample.
The UPDRS test-retest reliability values of .89 to .93 for the 3 subscales and total score were high, with MDC 95 values of 2, 4, 11, and 13, respectively. Minimal detectable change values for the UPDRS Mentation, Behavior, and Mood subscale should be used with caution due to its low internal consistency.
Discussion
The convenience sample of people with parkinsonism who participated in this study may be similar to patients with parkinsonism seen in outpatient clinics and wellness pro- 21, 32, 37, 57, 58, 60 The MDC 95 values calculated for the gait speed tests in this study are valid for individuals with PD. Of the 4 ambulation tests presented, clinicians should consider using both the comfortable and fast gait speeds to measure responsiveness to change over time because of the high test-retest reliability, normal distribution, and useful MDC scores in people with PD.
SF-36
Internal consistency values for all 8 SF-36 subscales in this study fell within the Cronbach alpha values reported in previous research. [65] [66] [67] [68] 70, 72, 73, [75] [76] [77] [78] [79] Similar to previous research, the Social Functioning scale had the poorest internal consistency (Tab. 1). Dr Steffen provided concept/idea/research design, project management, fund procurement, subjects, facilities/equipment, and institutional liaisons. Ms Seney provided writing and data collection and analysis.
